Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
Scinai Immunotherapeutics announces Positive Regulatory Feedback from PEI on path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb ($4.31, 0.00)
StreetAccount Activist Summary: Week of 11-Mar
Scinai Immunotherapeutics 12.96% shareholder Daniel Stone files 13D - 13D ($0.52, 0.00)
Powered by FactSet Research Systems Inc.